SAB Biotherapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 181.2K | $693.94K | 0.00% | New | 2026-03-31 |
| StateStreet | passive | 74.2K | $284.31K | 0.00% | Added+465.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.23 | — | — |
| 2026-03-09 | -0.17 | -0.41 | -142.12% |
| 2025-11-14 | -0.46 | 0.50 | +209.09% |
| 2025-08-07 | -0.80 | -1.09 | -36.93% |
| 2025-05-09 | -1.07 | -0.56 | +47.79% |
| 2025-03-31 | -1.21 | -0.98 | +18.93% |
| 2024-11-06 | -1.09 | -1.12 | -2.61% |
| 2024-08-08 | -1.15 | -0.79 | +31.10% |
| 2024-05-20 | -0.98 | -1.14 | -15.86% |
| 2024-03-29 | -0.64 | -6.39 | -898.69% |
| 2023-11-13 | -1.15 | -1.01 | +12.37% |
| 2023-08-21 | -1.45 | -1.29 | +10.76% |
| 2023-05-15 | -1.00 | -1.48 | -47.60% |
| 2023-04-14 | -1.15 | -1.81 | -57.25% |
| 2022-11-14 | -1.10 | -1.83 | -66.00% |
| 2022-08-10 | -1.00 | -1.50 | -50.50% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| SABS | +3.75% | -8.40% | -3.74% | +87.50% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | +0.78% | -3.57% | -0.30% | +74.88% |